Breast Cancer – Diagnosis and Treatment Prolonging Life: A Review
Keywords:Breast cancer, diagnosis, advancements, treatment, trials.
Breast cancer is a malignant tumour that starts either in the ducts or lobules, this can be generally differentiated as either in situ or invasive (in filtering) type. It is expected that in 2014 every 1 in 8 women are likely to develop invasive breast cancer during their lifetime when compared to a decade back where an average of 1 in 10 was seen. With this increase, breast cancer alone, roughly accounts for 25 to 30% of new cancer cases this year. Despite such diagnostic statistics, there are millions of survivors across the globe and this increasing rate can be attributed to the tremendous increase in advances in treatment and also early diagnosis. New drug delivery carriers like nanoparticles, liposomes, monoclonal antibodies, etc. are being used to improve the efficacy of therapy and for site specific delivery to reduce side effects. As a result of the constant effort by researchers, today the commercial market has a range of products apart from the conventional dosage forms like Herceptin (trastuzumab), a monoclonal antibody; the others in this class are Pertuzumab (Perjeta), Kadcyla (ado-trastuzumab emtansine) used for targeted delivery; Myocet (doxorubicin), a liposomal formulation and Paclitaxel nanoparticles all these are available as injections via intravenous route or infusion in few cases. There are yet certain other promising technologies like magnetic nanoparticle hyperthermia and cMethDNA assay a very assuring method to monitor recurrence of breast cancer by a simple blood test. This review will focus on the description of disease, diagnosis, current treatment therapies and ongoing research to provide better facilities.
American Cancer Society. What is breast cancer? Available at: http://www.cancer.org/cancer/breastcancer/detailedguide/ breast-cancer-what-is-breast-cancer
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29. http://dx.doi.org/10.3322/caac.21208
Australian Institute of Health and Welfare 2012. Cancer incidence projections: Australia, 2011 to 2020. Cancer Series no. 66. Cat. No. CAN 62. Canberra: AIHW.
Breastcancer.org. what is breast cancer? Available at: http://www.breastcancer.org/symptoms/understand_bc/what_is_bc
National Cancer Institute. Cellular classification of Breast cancer. Available at: http://www.cancer.gov/cancertopics/ pdq/treatment/breast/healthprofessional/page2
Yeatman TJ, Cantor AB, Smith TJ, et al. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 1995; 222(4): 549-59; discussion 559-61. http://dx.doi.org/10.1097/00000658-199522240-00012
Carter BA, Page DL. Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Hum Pathol 2004; 35(9): 1051-2. http://dx.doi.org/10.1016/j.humpath.2004.08.001
American Cancer Society. Signs and symptoms of breast cancer. Available at: http://www.cancer.org/cancer/ breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-signs-symptoms-br-ca
WebMD. Understanding breast cancer-Symptoms. Available at: http://www.webmd.com/breast-cancer/guide/under-standing-breast-cancer-symptoms
Henry P. Leis, Jr. Early Signs and Symptoms of Breast Cancer. West J Med 1980; 133(3): 225.
American Cancer Society. Breast cancer overview. Available at: http://www.cancer.org/acs/groups/cid/documents/ webcontent/003037-pdf.pdf
Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J 2008; 14: 3-13. http://dx.doi.org/10.1111/j.1524-4741.2007.00515.x
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Rev Cancer 2004; 4: 665-76. http://dx.doi.org/10.1038/nrc1431
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers in breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-69. http://dx.doi.org/10.1158/1055-9965
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A pathological approach. In: Laura Boehnke Michaud, Chad M. Barrnett and Francisco J. Esteva, editors. Breast cancer. 8th edition. The McGraw-Hill Companies 2011; pp. 2227-70.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12. http://dx.doi.org/10.1001/jama.291.14.1701
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The women’s health initiative randomized trial. JAMA 2003; 289(24): 3243-53. http://dx.doi.org/10.1001/jama.289.24.3243
Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-32. http://dx.doi.org/10.1056/NEJMoa013202
Walter C. Willett, Meir J. Stampfer, Graham A. Colditz, BA, Hennekens CH, Speizer FE. Dietary Fat and the Risk of Breast Cancer. N Engl J Med 1987; 316: 22-8. http://dx.doi.org/10.1056/NEJM198701013160105
Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. N Engl J Med 2004; 351: 427-37. http://dx.doi.org/10.1056/NEJMoa031759
Eastern Oncology Cooperative Group. Oncotype DX Assay fact sheet. Available at: http://www.ecog.org/general/ gendocs/tailorx_oncodxfact.pdf
Bernards R. Mamma Print, the story of the 70-gene profile. The Netherlands Cancer Institute, Amsterdam. Available at: http://www.belgianbreastmeeting.be/archives/bbs2008/materials/saturday/2008100401.pdf
National Health Service, United Kingdom. Treating breast cancer. Available at: http://www.nhs.uk/Conditions/Cancer-of-the-breast-female/Pages/Treatment.aspx
Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 2009; 16(7): 1959-72. http://dx.doi.org./10.1245/s10434-009-0452-2
National cancer institute. Hormone Therapy for Breast Cancer. Available at: http://www.cancer.gov/cancertopics/ factsheet/Therapy/hormone-therapy-breast
National cancer institute. Drugs approved for breast cancer. Available at: http://www.cancer.gov/cancertopics/druginfo/ breastcancer http://dx.doi.org/10.1002/1097-0142(197507)36:1<90::AID-CNCR2820360104>3.0.CO;2-H
BreastCancerTrials.org. All trials and new trials. Available at: https://www.breastcancertrials.org/bct_nation/browse_trials.seam?categoryString=All&ignp=1&pageRecord=0&cid=151
Conlin AK, Seidman AD, Bach A., et al.. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010; 10: 281-287. http://dx.doi.org/10.3816/CBC/2010.n.036
Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010; 10: 81-86. http://dx.doi.org/10.3816/CBC.2010.n.011
Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane (R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20: 449-53. http://dx.doi.org/10.1093/annonc/mdn661
van Vlerken LE, Amiji MM. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006; 3(2): 205-16. http://dx.doi.org/10.1517/17425247.3.2.205
Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006; 7: 657-67. http://dx.doi.org/10.1016/S1470-2045(06)70793-8
Ahmed M, Douek M. The Role of Magnetic Nanoparticles in the Localization and Treatment of Breast Cancer. BioMed Research International 2013; Article ID 281230. http://dx.doi.org/10.1155/2013/281230
Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc-Nanobiotechnol 2005; 152(1). http://dx.doi.org/10.1049/ip-nbt:20055018
Hilgera I, Hergtb R, Kaiser WA. Towards breast cancer treatment by magnetic heating. Journal of Magnetism and Magnetic Materials 2005; 293: 314-319. http://dx.doi.org/10.1016/j.jmmm.2005.02.026
Role of magnetic nanoparticles in breast cancer treatment, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center. Available at: http://www.sciencedaily.com/releases/ 2014/04/140407090226.htm
Huang HS, Hainfeld JF. Intravenous magnetic nanoparticle cancer hyperthermia. International Journal of Nanomedicine 2013; 8: 2521-32. http://dx.doi.org/10.2147/IJN.S43770
Cai W, Gao T, Hong H, et al. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl 2008; 2008(1): 17-32. http://dx.doi.org/10.2147/NSA.S3788
Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008; 4(4): 273-82. http://dx.doi.org/10.1016/j.nano.2008.06.002
Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2. http://dx.doi.org/10.1038/380561a0
O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs. conventional doxorubicin for firstline treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9. http://dx.doi.org/10.1093/annonc/mdh097
Brown S, Khan DR. The Treatment of Breast Cancer Using Liposome Technology. J Drug Deliv 2012; 2012: 212965. http://dx.doi.org/10.1155/2010/212965
Lee K, Cui Y, Lee LP, Irudayaraj J. Quantitative imaging of single mRNA splice variants in living cells. Nat Nanotechnol 2014; 9(6): 474-80. http://dx.doi.org/10.1038/nnano.2014.73
Gautherie M, Gros CM. Breast thermography and cancer risk prediction. Cancer 1980; 45: Sl-56.
Breastcancer.org. Thermography. Available at: http://www. breastcancer.org/symptoms/testing/types/thermography